Cancer drug from Aeterna, Keryx receives fast-track status

12/2/2009 | Reuters

The FDA granted fast-track designation to KRX-0401, an experimental cancer drug from Aeterna Zentaris and Keryx Biopharmaceuticals. Aeterna is testing the product in a Phase II trial to treat multiple tumor types and intends to conduct a late-stage study for multiple myeloma.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC